Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP468091.RAgRQVZ4TP118J6TCE945pK77qviUCsr6wEVlhjAO7LKM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP468091.RAgRQVZ4TP118J6TCE945pK77qviUCsr6wEVlhjAO7LKM130_assertion type Assertion NP468091.RAgRQVZ4TP118J6TCE945pK77qviUCsr6wEVlhjAO7LKM130_head.
- NP468091.RAgRQVZ4TP118J6TCE945pK77qviUCsr6wEVlhjAO7LKM130_assertion description "[The anti-CD20 monoclonal antibody rituximab has been less successful in treating chronic lymphocytic leukemia (CLL) than lymphoma, possibly due to the lower density of CD20 on B lymphocytes from CLL patients than on those from lymphoma patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP468091.RAgRQVZ4TP118J6TCE945pK77qviUCsr6wEVlhjAO7LKM130_provenance.
- NP468091.RAgRQVZ4TP118J6TCE945pK77qviUCsr6wEVlhjAO7LKM130_assertion evidence source_evidence_literature NP468091.RAgRQVZ4TP118J6TCE945pK77qviUCsr6wEVlhjAO7LKM130_provenance.
- NP468091.RAgRQVZ4TP118J6TCE945pK77qviUCsr6wEVlhjAO7LKM130_assertion SIO_000772 18794139 NP468091.RAgRQVZ4TP118J6TCE945pK77qviUCsr6wEVlhjAO7LKM130_provenance.
- NP468091.RAgRQVZ4TP118J6TCE945pK77qviUCsr6wEVlhjAO7LKM130_assertion wasDerivedFrom befree-20140225 NP468091.RAgRQVZ4TP118J6TCE945pK77qviUCsr6wEVlhjAO7LKM130_provenance.
- NP468091.RAgRQVZ4TP118J6TCE945pK77qviUCsr6wEVlhjAO7LKM130_assertion wasGeneratedBy ECO_0000203 NP468091.RAgRQVZ4TP118J6TCE945pK77qviUCsr6wEVlhjAO7LKM130_provenance.